Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (10972)	11/7/2016 5:53:35 PM
From: tuck	Respond to of 12215

Pretty tough on my morale, seeing adap add fludarabine just as juno is scapegoating with it. But Kite carries on with Fludarabine The gist being that Kite is using much lower doses of the preconditioning regime. For ADAP, I would like to see more color on that subject, and the preclinical data they talked of supporting the switch to Flu. They didn't point to anything published. Maybe I could ask IR if they intend to release said data? I'm afraid to add without knowing what doses they are using in the preconditioning with Flu, and how the mice responded to it. Cheers, Tuck

To: scaram(o)uche who wrote (10972)	11/9/2016 5:51:08 PM
From: tuck	Read Replies (1) \| Respond to of 12215

ADAP: Well, the partial hold is off, so maybe that helps the morale a bit. Still want to see the actual preclinical data re Flu. Cheers, Tuck

To: scaram(o)uche who wrote (10972)	11/17/2017 3:50:56 PM
From: tuck	Respond to of 12215

You see this? Patient death in ADAP MAGE-A10 trial deemed not treatment related, but there are questions . . . ADAP MAGE-A10 death Cheers, Tuck